Objective: To determine the issue of preoperative therapy with angiotensin-converting enzyme (ACE) inhibitors onward clinical outcome after cardiovascular surgery Study: Inception cohort.

Setting: A tertiary care 54-bed cardiothoracic ICU.

Patients: All admissions to an ICU throughout a 42-month period after cardiovascular surgery

Intervention: Extraction of preoperative, operative, and ICU data from a database.

Outcome measures: Incidence of acute organ dysfunction, long duration of mechanical ventilation, ICU stay, and death after cardiovascular surgery

Results: The subject of attention cohort consisted of four groups: normal or moderately impaired left ventricular function command (group A, n=6,400); normal or moderately impaired left ventricular function treated with ACE inhibitors (group B n=1375); harsh left ventricular dysfunction control (group C n= 1905); and stiff left ventricular dysfunction treated with ACE inhibitors (group D n=1650) The incidence of three or more organ dysfunction was similar onward comparison of group A v cluster B (5% vs 6%) or arrange C vs group D (15% v 13%) There were no differences in the total duration of mechanical ventilation or fulness of stay in the ICU in clump A vs group B or clump C vs group D. Death occurr in 2% of assign places tos A and B, and at 6% in assemblages C and D. Preoperative relentless left ventricular dysfunction in the pair groups C and D was associated with an increased incidence of three or more organ dysfunction, duration of mechanical ventilation, amplification of stay in ICU, and death after surgery Multivariate analysis indicated that therapy with ACE inhibitors did not affect the clinical result after cardiovascular surgery.

Conclusion: Preoperative therapy with ACE inhibitors did not influence the clinical issue after cardiac surgery. It is unlikely that therapy with ACE inhibitors can alter the clinical sequelae of cardiopulmonary bypass and cardiac surgical proceedings performed in high-risk patients because of underlying inexorable left ventricular dysfunction.

(CHEST 1998; 114:487-494)

Key words: angiotensin; cardiovascular surgery; inhibitors; organ dysfunction; outcome

Abbreviations: ACE=angiotensin-converting enzyme; CABG=coronary artery bypass graft

Multiple organ dysfunction syndrome remains a general cause of death after cardiovascular surgery[12] Several endogenous vasoactive substances and inflammatory mediators have been proposeed to induce acute organ injury and dysfunction.[3] Ischemia and reperfusion injury ofttimes associated with abnormal pattern of microvascular vital fluid flow contributed to subsequent disclosure of multiple organ dysfunction syndrome Neuronal, hormonal, and tissue production of vasoactive substances contributes to pathophysiologic derangement of the macrocirculation and microcirculation perfusion patterns during cardiopulmonary bypass.[4] Angiotensin II, which is united of the most potent vasoactive substances released during cardiopulmonary bypass, disrupts perfusion and regional oxygen utilization of splanchnic organs.[5,6] Angiotensin II has direct and indirect vasoconstrictive issues on the macrovasculature and microvasculature.[7] Angiotensin II augments the release and action of other endogenous vasoconstrictors like as catecholamines and endothelin and also inhibits the synthesis of vasodilators from vascular endothelium like as nitric oxide and prostacyclin.[8,9]

Angiotensin-converting enzyme (ACE) inhibitors are widely used for the treatment of systolic and diastolic left ventricular dysfunction.[10] ACE inhibitors were reported to improve organ function, overset structural abnormalities of the cardiovascular hypothesis and to prolong survival in patients with chronic heart failure.[11] ACE inhibitors are used therapeutically to arrest the synthesis of angiotensin II and hence attenuate the activation of several neurohumoral mechanisms that are deleterious in heart failure. ACE inhibitors abate the vasoconstrictive imports of angiotensin II, facilitate the vasodilator activity of tissue bradykinin and prostaglandins, and scavenge oxygen unrestrained radicals generated during ischemia and reperfusion injury.[7]

The benefits from therapy with ACE inhibitors in heart failure were extrapolated to improve clinical consequence of patients undergoing cardiovascular surgery[4512] In theory, ACE inhibitors can support better patterns of vital fluid flow at both the macrocirculation and microcirculation flushs and potentially protect against ischemia and reperfusion injury triggered at cardiopulmonary bypass. However, to our knowledge, there are no clinical studies to support that ACE inhibitors influenced either the incidence of acute organ dysfunction or clinical consequence after cardiopulmonary bypass. The circulating study aimed to examine if preoperative therapy with ACE inhibitors decreased the incidence of acute organ dysfunction, duration of mechanical ventilation, and death after cardiovascular surgery The meanings of ACE inhibitors on clinical issue were examined in patients stratified by means of preoperative left ventricular function as described previously for clinical evaluation of efficacy of ACE inhibitors.[9] The inquiry design was an inception cohort with a nonrandomized ease-control comparison.

...